Tumors or cancer of the LUNG.
Corrosive oxidant, explosive; additive to diesel and rocket fuels; causes skin and lung irritation; proposed war gas. A useful reagent for studying the modification of specific amino acids, particularly tyrosine residues in proteins. Has also been used for studying carbanion formation and for detecting the presence of double bonds in organic compounds.
Toxic, possibly carcinogenic, monomer of neoprene, a synthetic rubber; causes damage to skin, lungs, CNS, kidneys, liver, blood cells and fetuses. Synonym: 2-chlorobutadiene.
Materials applied to fabrics, bedding, furniture, plastics, etc. to retard their burning; many may leach out and cause allergies or other harm.
A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)
Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE).
Pathological processes involving any part of the LUNG.
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The transference of either one or both of the lungs from one human or animal to another.
Neoplasms containing cyst-like formations or producing mucin or serum.
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
A malignant epithelial tumor with a glandular organization.
Tumors or cancer of the THYROID GLAND.
DNA present in neoplastic tissue.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumors or cancer of the LIVER.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
The volume of air contained in the lungs at the end of a maximal inspiration. It is the equivalent to each of the following sums: VITAL CAPACITY plus RESIDUAL VOLUME; INSPIRATORY CAPACITY plus FUNCTIONAL RESIDUAL CAPACITY; TIDAL VOLUME plus INSPIRATORY RESERVE VOLUME plus functional residual capacity; or tidal volume plus inspiratory reserve volume plus EXPIRATORY RESERVE VOLUME plus residual volume.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.
Water content outside of the lung vasculature. About 80% of a normal lung is made up of water, including intracellular, interstitial, and blood water. Failure to maintain the normal homeostatic fluid exchange between the vascular space and the interstitium of the lungs can result in PULMONARY EDEMA and flooding of the alveolar space.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Tumors or cancer of the ENDOCRINE GLANDS.
Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.
Tumors or cancer of the NOSE.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A benign epithelial tumor with a glandular organization.
Tumors or cancer of the EYE.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the SALIVARY GLANDS.
Tumors or cancer located in bone tissue or specific BONES.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Tumors or cancer of the UTERUS.
Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer of the INTESTINES.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Lung damage that is caused by the adverse effects of PULMONARY VENTILATOR usage. The high frequency and tidal volumes produced by a mechanical ventilator can cause alveolar disruption and PULMONARY EDEMA.
Neoplasms composed of more than one type of neoplastic tissue.
Tumors or cancer of the COLON.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Tumors or cancer of the MANDIBLE.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Infection of the lung often accompanied by inflammation.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Cancer or tumors of the MAXILLA or upper jaw.
The excision of lung tissue including partial or total lung lobectomy.
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Tumors or cancer of the anal gland.
Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Tumors or cancer of the MEDIASTINUM.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A form of alveolitis or pneumonitis due to an acquired hypersensitivity to inhaled antigens associated with farm environment. Antigens in the farm dust are commonly from bacteria actinomycetes (SACCHAROPOLYSPORA and THERMOACTINOMYCES), fungi, and animal proteins in the soil, straw, crops, pelts, serum, and excreta.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer of the DUODENUM.
A cell line derived from cultured tumor cells.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Inhaling and exhaling the smoke of burning TOBACCO.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the MOUTH.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
Tumors or cancer of the STOMACH.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Tumors or cancer of the human BREAST.
Tumors or cancers of the ADRENAL CORTEX.
The circulation of the BLOOD through the LUNGS.
Tumors or cancer of the URINARY BLADDER.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the TONGUE.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Experimentally induced tumors of the LIVER.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.
Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.
Tumors or cancer of the VAGINA.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
The mucous membrane lining the RESPIRATORY TRACT, including the NASAL CAVITY; the LARYNX; the TRACHEA; and the BRONCHI tree. The respiratory mucosa consists of various types of epithelial cells ranging from ciliated columnar to simple squamous, mucous GOBLET CELLS, and glands containing both mucous and serous cells.
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
Tumors or cancer of the PARANASAL SINUSES.
Surgical removal of the pancreas. (Dorland, 28th ed)
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
The complex of political institutions, laws, and customs through which the function of governing is carried out in a specific political unit.

Human papillomavirus DNA in adenosquamous carcinoma of the lung. (1/26018)

AIM: To investigate the presence of human papillomavirus (HPV) DNA in adenosquamous carcinoma of the lung--which is relatively common in Okinawa but not in mainland Japan--and examine its histological features. METHODS: Of 207 cases where primary lung cancers were surgically removed between January 1995 and June 1997 in Okinawa, 23 were adenosquamous carcinoma. HPV was detected by non-isotopic in situ hybridisation (NISH) and polymerase chain reaction (PCR) amplification with primers specific for E6 and E7 regions of the HPV genome. PCR products were analysed by Southern blotting. Immunohistochemical determination of high molecular weight cytokeratin (HMC) and involucrin was also carried out. RESULTS: 18 cases were positive for HPV DNA by PCR and NISH. HPV types 6, 11, 16, and 18 were found. Seven cases were dual positive for different types of HPV. Using NISH, HPV was also found in the squamous cell components and in neighbouring enlarged adenocarcinoma cells. The HMC and involucrin were demonstrated immunohistochemically in the same areas. CONCLUSIONS: HPV DNA was found in a high proportion (78.3%) of adenosquamous carcinomas in Okinawa, a region where HPV has previously been shown to be prevalent in squamous cell carcinoma of the lung. The adenocarcinoma cells adjacent to the squamous cell carcinoma component were enlarged and positive for HPV, HMC, and involucrin. This is thought to indicate the transition from adenocarcinoma to squamous cell carcinoma.  (+info)

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. (2/26018)

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. (3/26018)

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (4/26018)

Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (5/26018)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (6/26018)

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.  (+info)

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. (7/26018)

The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.  (+info)

Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. (8/26018)

Three different membrane-type matrix metalloproteinases (MT1-, MT2-, and MT3-MMPs) are known to activate in vitro the zymogen of MMP-2 (pro-MMP-2, progelatinase A), which is one of the key MMPs in invasion and metastasis of various cancers. In the present study, we have examined production and activation of pro-MMP-2, expression of MT1-, MT2-, and MT3-MMPs and their correlation with pro-MMP-2 activation, and localization of MMP-2, MT1-MMP, and MT2-MMP in human astrocytic tumors. The sandwich enzyme immunoassay demonstrates that the production levels of pro-MMP-2 in the anaplastic astrocytomas and glioblastomas are significantly higher than that in the low-grade astrocytomas (P<0.05 and P<0.01, respectively), metastatic brain tumors (P<0.05), or normal brains (P<0.01). Gelatin zymography indicates that the pro-MMP-2 activation ratio is significantly higher in the glioblastomas than in other astrocytic tumors (P<0.01), metastatic brain tumors (P<0.01), and normal brains (P<0.01). The quantitative reverse transcription polymerase chain reaction analyses demonstrate that MT1-MMP and MT2-MMP are expressed predominantly in glioblastoma tissues (17/17 and 12/17 cases, respectively), and their expression levels increase significantly as tumor grade increases. MT3-MMP is detectable in both astrocytic tumor and normal brain tissues, but the mean expression level is approximately 50-fold lower compared with that of MT1-MMP and MT2-MMP in the glioblastomas. The activation ratio of pro-MMP-2 correlates directly with the expression levels of MT1-MMP and MT2-MMP but not MT3-MMP. In situ hybridization indicates that neoplastic astrocytes express MT1-MMP and MT2-MMP in the glioblastoma tissues (5/5 cases and 5/5 cases, respectively). Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2. In situ zymography shows gelatinolytic activity in the glioblastoma tissues but not in the normal brain tissues. These results suggest that both MT1-MMP and MT2-MMP play a key role in the activation of pro-MMP-2 in the human malignant astrocytic tumors and that the gelatinolytic activity is involved in the astrocytic tumor invasion.  (+info)

Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021 Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data Veracyte, Inc. (Nasdaq: VCYT) today announced preliminary clinical data showing that the companys noninvasive nasal swab test - the first of its kind - can enable early lung cancer detection and diagnosis so that more lives can be saved. The new findings specifically show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. The findings will be presented today at the annual meeting of the American College of Chest Physicians® (CHEST) in New Orleans. Early ...
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Lung cancer;neutrophil to lymphocyte ratio;prognostic factors;C reactive protein; Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or treatment has been shown to be an indicator of prognosis for cancer. The aim of this study was to investigate the value of NLR as a prognostic factor and the correlation between NLR and other probable clinical prognostic factors in non small cell lung cancer patients prior to treatment. Materials and Methods: Data of patients who were diagnosed with non-small cell lung cancer in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR was calculated before the application of any treatment. Results: A total of 299 patients, 270 (90%) males and 29 (10
Since this squamous cell lung cancer is being considered as destructive neoplasm in lungs, additional care is paid towards incorporating the effective supportive therapy in the regular anti cancerous therapy, involving multi drug combinations. The supportive therapy may include usage of suitable corticosteroid drugs like prednisolone in a routine form and it is noteworthy to mention that in some patients, a repository form of this corticosteroid may also be used to fulfill the need of constant delivery.. Surgery is also being considered as therapy in cases of squamous cell lung cancer. But, if the spread of this is over a wide area, it becomes impossible.. The squamous cell lung cancer in many patients tends to spread to other tissues including kidney or bone. Suppose, if it spreads to bones, most of the times, mandible or skull may get affected and in such cases increased density with occurrence of periosteal new bones may be noticed.. Squamous cell lung cancer at times need confirmation from ...
Non‑small cell lung cancer (NSCLC) constitutes the majority of all lung‑cancer cases. Aquaporin 5 (AQP5) may be involved in NSCLC by promoting lung‑cancer initiation and progression. The present study aimed to determine the role of AQP5 in migration and angiogenesis using NSCLC cells and HUVECs. AQPs 1, 3, 4, 5, 8 and 9 were screened in the NSCLC cell line H1299, and the present results showed that AQP5 mRNA was upregulated compared with the other AQP genes. At the protein level, AQP5 was significantly increased in H1299 cells compared with 16HBE cells. AQP5 knockdown in H1299 cells significantly decreased cell migration compared with untransfected cells, as demonstrated by both Transwell and wound closure assays. The present study further investigated H1299 ability to promote HUVEC vascularisation. The supernatants of both transfected and untransfected H1299 cells were used as conditioned medium for HUVECs, and tube formation was measured. The supernatant of AQP5‑downregulated cells ...
In an interview with SurvivorNet, Dr. Ronald Natale discussed current clinical trials testing drug Tagrisso on early stage lung cancer patients. While findings have been historic, there is still controversy surrounding how this drug impacts overall survivor rate.
BackgroundStereotactic body radiotherapy (SBRT) demonstrates excellent local control in early stage lung cancer, however a quarter of patients develop recurrence or distant metastasis. Transforming growth factor-beta (TGF-β) supports metastasis and treatment resistance, and angiote...
TY - JOUR. T1 - Mutational analysis of multiple lung cancers. T2 - Discrimination between primary and metastatic lung cancers by genomic profile. AU - Goto, Taichiro. AU - Hirotsu, Yosuke. AU - Mochizuki, Hitoshi. AU - Nakagomi, Takahiro. AU - Shikata, Daichi. AU - Yokoyama, Yujiro. AU - Oyama, Toshio. AU - Amemiya, Kenji. AU - Okimoto, Kenichiro. AU - Omata, Masao. PY - 2017/1/1. Y1 - 2017/1/1. N2 - In cases of multiple lung cancers, individual tumors may represent either a primary lung cancer or both primary and metastatic lung cancers. Treatment selection varies depending on such features, and this discrimination is critically important in predicting prognosis. The present study was undertaken to determine the efficacy and validity of mutation analysis as a means of determining whether multiple lung cancers are primary or metastatic in nature. The study involved 12 patients who underwent surgery in our department for multiple lung cancers between July 2014 and March 2016. Tumor cells were ...
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. Clinical trials have reported its effectiveness in the treatment of brain metastases from non-small cell lung cancer by overcoming the blood-brain barrier. Gefitinib is generally regarded as a relatively safe agent, and several reports have described its efficacy in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a poor performance status. We herein described two patients with brain metastasis from non-small cell lung cancer who achieved the total regression of metastasis with the administration of gefitinib. A 70-year-old Japanese woman was referred to our hospital with a severe cough. Brain magnetic resonance imaging revealed a metastatic lesion in the left temporal lobe. The tumor was positive for an epidermal growth factor receptor L858R mutation in exon 21 using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method. She was treated with 250 mg
The Small Cell Lung Cancer Treatment Market is driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents. The market growth is estimated to occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan.. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Small Cell Lung Cancer Treatment Market ResearchReport at- http://www.absolutereports.com/opportunityanalyzer-small-cell-lung-cancer-sclc-opportunity-analysis-and-forecasts-to-2024-10112598. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor Yervoy will be the first immunotherapy to be introduced in the market. This drug is being developed by Bristol-Myers Squibb and will be launched in 2016 across the seven major markets.. The increase in rates of the disease across the five European markets and Japan, at a CAGR of 1.49% over the forecast period is estimated to further bolster the Small Cell Lung Cancer treatment ...
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease ...
Since 2000, the WHPP Early Lung Cancer Detection (ELCD) Program has provided low-dose chest CT scans to U.S. Department of Energy (DOE) workers, with the primary purpose of detecting lung cancers early. The WHPP ELCD Program serves DOE workers from nine sites in the DOE complex: Idaho National Laboratory (INL); the K-25, Paducah and Portsmouth gaseous diffusion plants (GDPs); the Mound and Fernald closure sites; the Nevada National Security Site (formerly the Nevada Test Site); Oak Ridge National Laboratory; and Y-12. As of September 2015, over 13,000 DOE workers have received low-dose screening CT scans through the ELCD Program; 136 lung cancers have been detected, with the majority (71%) found in early stages.. WHPP participants with an elevated risk of lung cancer based on age, smoking and work history are currently offered annual screening, as well as interim follow-up CT scans, if needed.. A low-dose screening CT scan of the chest uses much less radiation than a standard, full-dose CT scan ...
An increasing number of chromosomal aberrations is being identified in solid tumors providing novel biomarkers for various types of cancer and new insights into the mechanisms of carcinogenesis. We applied next generation sequencing technique to analyze the transcriptome of the non-small cell lung carcinoma (NSCLC) cell line H2228 and discovered a fusion transcript composed of multiple exons of ALK (anaplastic lymphoma receptor tyrosine kinase) and PTPN3 (protein tyrosine phosphatase, nonreceptor Type 3). Detailed analysis of the genomic structure revealed that a portion of genomic region encompassing Exons 10 and 11 of ALK has been translocated into the intronic region between Exons 2 and 3 of PTPN3. The key net result appears to be the null mutation of one allele of PTPN3, a gene with tumor suppressor activity. Consistently, ectopic expression of PTPN3 in NSCLC cell lines led to inhibition of colony formation. Our study confirms the utility of next generation sequencing as a tool for the ...
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell lung cancer (NSCLC) who achieve radiographic regressions to the EGFR inhibitor gefitinib. One of these mutations, L858R (Leu→Arg), is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment. We characterized nine NSCLC cell lines (three isolated from patients with bronchioloalveolar carcinoma and six isolated from patients with adenocarcinoma) for their in vitro sensitivity to gefitinib. Of these, only H3255 (EGFRL858R) and H1666 (EGFRWT) are sensitive to gefitinib with IC50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects of gefitinib on H3255 and cell lines containing wild-type EGFR that are either sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. Gefitinib treatment (1 μmol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) ...
[130 Pages Report] Check for Discount on United States Non Small Cell Lung Cancer Therapeutics Industry 2016 Market Research Report report by QYResearch Group. The United States Non Small Cell Lung Cancer Therapeutics Industry...
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early stage NSCLC. Several studies have reported high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC ...
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Wright on life chances with non small cell lung cancer: Stage 1 nsclc; surgical resection, appr70%5yrsurv stage2nsclc;surgery apprx. 30-35% 5 yr survival. for topic: Life Chances With Non Small Cell Lung Cancer
Between 1990 and 2011, almost 720,000 people were diagnosed with lung cancer. During this time, the number of male lung cancer diagnoses declined, whereas the number of female lung cancer diagnoses increased. Lung cancer incidence increases sharply after middle age. More than 75% of lung cancers are diagnosed in people over the age of 65. The difference in the trends of lung cancer incidence among men and women is even more pronounced when age is taken into account. The sharp decrease in the incidence of male lung cancer over the past two decades reflects the decline in smoking prevalence among men. However, due to the rise in women who took up smoking after World War II, the incidence among women continues to increase. The difference in smoking prevalence between men and women has given rise to a dramatic change in the male to female lung cancer incidence ratio from 3:1 in 1990 to 3:2 in 2011.. ...
For patients with Stage III non-small cell lung cancer, prophylactic (preventive) radiation therapy to the brain reduces the risk of brain metastases but carries a risk of memory problems and doesnt appear to improve overall survival. These results were published in the Journal of Clinical Oncology.. Lung cancer remains the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.. One of the sites to which NSCLC can spread (metastasize) is the brain. Brain metastases can have a profound effect on survival and quality of life.. Prophylactic cranial irradiation (PCI) refers to the administration of radiation to the brain before brain metastases become apparent. The goal of PCI is the prevention of brain metastases. Previous studies have suggested that PCI can reduce the occurrence of brain metastases, but PCI has not become a part of routine NSCLC care because of concern about side effects and lack of evidence that ...
Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split into two cohorts depending on their ...
TY - JOUR. T1 - Inactivation of LLC1 gene in nonsmall cell lung cancer. AU - Hong, Kyeong Man. AU - Yang, Sei Hoon. AU - Chowdhuri, Sinchita Roy. AU - Player, Audrey. AU - Hames, Megan. AU - Fukuoka, Junya. AU - Meerzaman, Daoud. AU - Dracheva, Tatiana. AU - Sun, Zhifu. AU - Yang, Ping. AU - Jen, Jin. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Serial analysis of gene expression studies led us to identify a previously unknown gene, c20orf85, that is present in the normal lung epithelium but absent or downregulated in most primary non-small cell lung cancers and lung cancer cell lines. We named this gene LLC1 for Low in Lung Cancer 1. LLC1 is located on chromosome 20q13.3 and has a 70% GC content in the promoter region. It has 4 exons and encodes a protein containing 137 amino acids. By in situ hybridization, we observed that LLC1 message is localized in normal lung bronchial epithelial cells but absent in 13 of 14 lung adenocarcinoma and 9 out of 10 lung squamous carcinoma samples. Methylation at CpG ...
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play important roles during branching morphogenesis of embryonic salivary glands and lungs. However its function in malignant tumors is largely unknown. The aim of this study is to investigate the clinicopathological significance and possible function of Btbd7 in non-small cell lung cancer. Immunohistochemistry and Western blotting were used to investigate Btbd7 expression in non-small cell lung cancer and lung tissues. The clinicopathological association and the overall survival was analyzed. In vitro experiments were performed using siRNA to investigate the function of Btbd7 in lung cancer cells. Btbd7 expression was elevated in non-small cell lung cancer tissues compared to normal lung tissues. Increased Btbd7 expression was significantly associated with lymph node metastasis, reduced E-cadherin
The purpose of this study is to find out if adding the study drug, nivolumab, after surgery and chemotherapy will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the bodys immune system to attack any cancer cells that may remain after surgery.
Metastatic lung cancer survival rate is very low. This kind of lung cancer can prolong life but only for minimal months. It is a stage that involves cancer
TY - JOUR. T1 - Comparison study of quality of life in advanced lung cancer patients on tyrosine kinase inhibitor and platinum doublet chemotherapy. AU - Udupa, K.. AU - Rajendranath, R.. AU - Sagar, T. G.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - INTRODUCTION: Lung cancer is most common cause of cancer death in the world. Most of the patient are diagnosed in the late stages and receive only palliative treatment. The main objective of the palliative chemotherapy is to improve survival as well as the quality of life (QOL). QOL is the most neglected dimension of cancer care in developing countries like India. Palliative chemotherapeutic agent which has minimum toxicity and prolongs the survival of metastatic cancer patients is the need of the day. MATERIALS AND METHODS: In this study, 43 metastatic adenocarcinoma of lung patients of South Indian origin were enrolled. Twenty patients out of this 43 were epidermal growth factor receptor (EGFR) mutation positive and were started on tyrosine kinase ...
Data & statistics on Lung cancer mortality by ethnic group age group and sex: Lung cancer mortality, by ethnic group, age group and sex, 2011, Lung Cancer Mortality Rates by Sex and Ethnicity 1987-1995 Age-adjusted lung cancer mortality rates by sex and ethnicity for the combined period 1990 through 1995, along with their 95% confidence intervals and the rate ratios of each group compared to White rates, are shown in Table 21. (See also Figures 6 and 7, pp. 28-29) Table 21: Lung Cancer Mortality Rates and Rate Ratios by Ethnicity and Sex, ..., That the lung cancer mortality rates in North Denver women were higher than rates in the remainder of the Metro area in all race/ethnicity groups; the differences were statistically significant for all races combined, and white non-Hispanics. For males, lung cancer mortality rates in North Denver were higher than other Metro area rates for all races combined, white non-Hispanics, and Hispanics, but ......
TY - JOUR. T1 - XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers. AU - Yeh, Kun Tu. AU - Wu, Yi Hui. AU - Lee, Ming Ching. AU - Wang, Lee. AU - Li, Chien Te. AU - Chen, Chih Yi. AU - Lee, Huei. PY - 2012/3. Y1 - 2012/3. N2 - Background. Disease recurrence and distant metastasis are the major causes of death in resected non-small cell lung cancer (NSCLC). The prognostic marker for never-smokers with this disease remains to be identified. To improve patient outcome, establishing an adjacent molecular marker to predict relapse of NSCLC in never-smokers is needed. Methods. Three hundred two lung tumors from NSCLC patients and normal lung tissues from 68 noncancer subjects were enrolled to evaluate XPC (xeroderma pigmentosum group C) mRNA expression by quantitative real-time reverse transcriptase polymerase chain reaction. Receiver operating characteristic curve analysis was used to search for a feasible cutoff point of XPC mRNA levels for predicting ...
Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) account for at least 80% of all lung tumors and about 30% of them present with unresectable locally advanced disease at diagnosis (stage IIIA-IIIB) [1]. Until the mid 1980s standard treatment of patients with inoperable locally advanced NSCLC consisted of radiotherapy (RT) alone with a median survival time of 10 months[1]. From data about lung cancer population diagnosed in the second half of 1990s, overall survival at one and two years was estimated of 36% and 12% respectively[2].. Rates at 2 and 5 years of 15% and 5% respectively [3]. In attempts to improve the survival in these patients, chemotherapy was added to external beam irradiation. Several trials have been positive in favour of combined therapy [4-6]. More recently, other clinical trials have shown that, in selected patients (good performance status, age ≤ 75 years and minimal weight loss) concomitant platinum-based ...
Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer. We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR. For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; ...
TY - JOUR. T1 - Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. AU - Improta, Giuseppina. AU - Zupa, Angela. AU - Natalicchio, Maria Iole. AU - Sisinni, Lorenza. AU - Marinaccio, Anna. AU - Bozza, Giovanni. AU - Vita, Giulia. AU - Aieta, Michele. AU - Landriscina, Matteo. PY - 2018/1/31. Y1 - 2018/1/31. N2 - Exons 19-21 EGFR activating mutations are predictive biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, uncommon exon 19 EGFR mutations, due to their low frequency, have an uncertain biological and clinical significance and very little is known about their TKI sensitivity. This study was designed to describe the TKI sensitivity of a small cohort of lung adenocarcinomas bearing uncommon exon 19 mutations and to evaluate in silico the correlation between frame-shift exon 19 mutations and EGFR sequence/structure modification. Among 1168 NSCLCs screened for ...
TY - JOUR. T1 - Predictors of primary lung cancer in a solitary pulmonary lesion after a previous malignancy. AU - Nakadate, Akie. AU - Nakadate, Masashi. AU - Sato, Yasunori. AU - Nakagawa, Tassei. AU - Yoshida, Katsuya. AU - Suzuki, Yoshio. AU - Yoshida, Yukihiro. PY - 2017/12/1. Y1 - 2017/12/1. N2 - Objective: A solitary pulmonary lesion in patients with a history of malignancy may be either primary lung cancer or a metastatic lung tumor or benign nodule. We retrospectively examined the preoperative predictive factors for determining the type of pathology. Methods: We used an exact logistic regression analysis to identify radiological and clinical predictors of primary lung cancer. The study included 187 patients who underwent pulmonary resection for a solitary pulmonary lesion and had received previous treatment for a malignancy. Results: There were 107 patients with primary lung cancer, 74 with metastatic lung tumors, and 6 with benign lesions. The previous malignancy included colorectal ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Survival of Patients with Stage I Lung Cancer Detected on CT Screening
Effects of interferons and tumour necrosis factor-a on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. ...
1. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1-19 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30 3. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10 4. Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H. et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene. 2018;37:4300-12 5. Dragnev K, You M Fau - Wang Y, Wang Y Fau - Lubet R, Lubet R. Lung cancer chemoprevention: difficulties, promise and potential agents?. Expert Opin Investig Drugs. 2013;22:35-47 6. Li Q, Zhang D, Chen X, He L, Li T, Xu X. et al. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Scientific reports. 2015;5:16082 7. Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X. et al. Continuous ...
Although the following paper was published already 7 months ago (January 2010, in the British Medical Journal), and is no longer new news, I strongly feel that the information needs to be reinforced.. The authors conducted a review of 10 high-quality studies that evaluated the potential influence on survival in patients with lung cancer who quit smoking after their diagnosis. Most of the studies (9 out of 10) looked only at the effects of smoking in cessation in patients with early stage lung cancers.. What they found was quite remarkable: survival rates doubled among those patients who quit smoking after their diagnosis! In patients with early stage, non-small cell lung cancers, the 5-year survival rates were 33% vs. 70%, in smokers and non-smokers, respectively. In patients with limited stage small cell lung cancer, the 5-year survival rates were 29% vs. 63%, in smokers and non-smokers, respectively.. The authors concluded from their analysis that the doubling of survival was most likely due ...
During this years AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the teams most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.
San Antonio (TX), Bolton (MA). As originally published in International Clinical Trials, May 2015 - View PDF. In the fight against non-small cell lung cancer, all eyes have been on computed tomography imaging to aid early detection. But advances in the field are leading the oncology and radiology communities to consider novel measurement parameters and techniques to better assess tumour response.. Lung Cancer: Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined (colon, breast and pancreatic). In 2012, the estimate for new cases of lung cancer reached 226,160, with 164,770 deaths accounting for 27% of all cancer deaths. The five-year survival rate is low at 16%, often due to most patients having advanced disease at the time of presentation.. Non-small cell lung cancer (NSCLC) accounts for some 85% of lung cancer diagnoses. Fortunately for this subset of patients, surgery can often be curative, but only if ...
TY - JOUR. T1 - Circulating plasma DNA in non-small cell lung cancer patients is not influenced by inflammatory pulmonary conditions. AU - van der Drift, M.A.. AU - Hol, B.E.A.. AU - Klaassen, C.D.. AU - Prinsen, C.. AU - van Aarssen, Y.A.W.G.. AU - Dekhuijzen, P.N.R.. AU - van der Stappen, J.W.J.. AU - Thunnissen, F.B.J.M.. PY - 2009. Y1 - 2009. M3 - Article. VL - 4. SP - S903-S903. JO - Journal of Thoracic Oncology. JF - Journal of Thoracic Oncology. SN - 1556-0864. IS - 9. ER - ...
Objective: To report the median survival time in a contemporary cohort of dogs with primary lung tumors and intrathoracic nodal metastasis.Design: Retrospective Case Series.Animals (or sample): Dogs with primary lung tumors treated with lung lobectomy and lymph node biopsy.Procedures: The medical record database at Colorado State University was queried for dogs with primary lung tumors from January 1, 2005 to December 31, 2017. Patients were identified for inclusion if they had lung lobectomy and an intrathoracic lymph node biopsy performed. The median survival time (MST) for lymph node positive (LN+) and negative dogs (LN-) was calculated as well as the MST in dogs that did or did not receive adjuvant chemotherapy. Differences were compared between groups with significance set at p Results: The MST in LN+ dogs (n = 11) was 167 days which was not statistically different from LN- dogs (n = 29) at 456 days (p = 0.2407). No significant difference in the MST in LN+ dogs was identified between dogs that
TY - JOUR. T1 - MicroRNAs in non-small cell lung cancer. T2 - Gene regulation, impact on cancer cellular processes, and therapeutic potential. AU - Petrek, Hannah. AU - Yu, Ai Ming. PY - 2019/12/1. Y1 - 2019/12/1. N2 - Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of NSCLC biology is critical to improve the treatment of NSCLC. MicroRNAs (miRNAs or miRs) are a superfamily of genome-derived, small noncoding RNAs that govern posttranscriptional gene expression in cells. Functional miRNAs are commonly dysregulated in NSCLC, caused by genomic deletion, methylation, or altered processing, which may lead to the changes of many cancer-related pathways and processes, such as growth and death signaling, metabolism, angiogenesis, cell cycle, and epithelial to mesenchymal transition, as well as ...
Hello - My husband is a 33 year old non smoker and has been diagnosed with non small cell lung cancer in March 2012. He was not feeling well for a few months with a dry cough which turned into flu like symptoms. His PCP prescribed numerous meds and thought he had pneumonia. He came home from work one night and was complaining of blurred vision, fever & chills. I took him to the ER and he was admitted. The following morning he met with a pulmonary doctor who performed a bronchoscopy. From here, we were told that my husband had mold in his lungs. He was placed on medication for this. A month later he had a follow up with his doctor who informed him that mold was NOT in his lungs. My husband was sent for a CT scan & was told the following morning that he had a collapsed right lung. A chest tube was put in immediately & a right lung biopsy was done. This came back as cancer. We went for a second opinion & cancer was confirmed. My husband underwent a few surgical procedures & has 2 tumors in his ...
Effect of Ape1/Ref-1 on injury caused by stereotactic ablative radiotherapy in the treatment of early stage non-small cell lung cancer, Lei Han, Renzhi Yu, Xin Ni, Zenglei Zhang
Lung cancer is the leading cause of cancer-related mortality. Therapies against non-small cell lung cancer (NSCLC) are particularly needed, as this type of cancer is relatively insensitive to chemotherapy and radiation therapy. We recently identified GGTI compounds that are designed to block geranylgeranylation and membrane association of signaling proteins including the Rho family G-proteins. One of the GGTIs is P61A6 which inhibits proliferation of human cancer cells, causes cell cycle effects with G1 accumulation and exhibits tumor-suppressing effects with human pancreatic cancer xenografts. In this paper, we investigated effects of P61A6 on non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Three non-small cell lung cancer cell lines were used to test the ability of P61A6 to inhibit cell proliferation. Further characterization involved analyses of geranylgeranylation, membrane association and activation of RhoA, and anchorage-dependent and -independent growth, as well as cell cycle
Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy
TY - JOUR. T1 - Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. AU - Gjerstorff, Morten F. AU - Pøhl, Mette. AU - Olsen, Karen E. AU - Ditzel, Henrik J. PY - 2013. Y1 - 2013. N2 - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. However, little is known about the expression of other cancer/testis antigens in NSCLC. In the present study the expression of cancer/testis antigens GAGE, NY-ESO-1 and SP17 was investigated in patients with completely resected, early stage, primary NSCLC.. AB - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen ...
TY - JOUR. T1 - Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. T2 - Preliminary results comparing sequential phase II trials. AU - DeVore, R. F.. AU - Jagasia, M.. AU - Johnson, D. H.. PY - 1997/10/22. Y1 - 1997/10/22. N2 - Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion) in 51 patients with advanced non-small cell lung cancer. To facilitate outpatient administration, the regimen was modified to infuse paclitaxel over 1 hour. Between February 1995 and August 1996, 63 patients with advanced non-small cell lung cancer were accrued by the Vanderbilt Cancer Center and its affiliate network. The first four patients received paclitaxel 175 mg/ml2; all subsequent patients received paclitaxel 200 mg/m2. The carboplatin dose was determined using the Calvert formula, with a target area under the concentration-time curve of 6. ...
TY - JOUR. T1 - Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. T2 - The eastern cooperative oncology group results. AU - Chang, A. Y.. AU - Kim, K.. AU - Glick, J.. AU - Anderson, T.. AU - Karp, D.. AU - Johnson, D.. PY - 1993/3/3. Y1 - 1993/3/3. N2 - Background: Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents-taxol, merbarone, and piroxantrone-have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies. Purpose: Our randomized phase II study was designed to evaluate the efficacy and ...
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.
TY - JOUR. T1 - Use of MicroRNA expression levels to predict outcomes in resected stage i non-small cell lung cancer. AU - Duncavage, Eric. AU - Goodgame, Boone. AU - Sezhiyan, Ananth. AU - Govindan, Ramaswamy. AU - Pfeifer, John. PY - 2010/11. Y1 - 2010/11. N2 - Background: Despite undergoing curative resection, nearly a third of patients with stage I non-small cell lung cancer (NSCLC) die of recurrent disease. There are no reliable clinical or molecular predictors of relapse in patients with resected stage I NSCLC. Identifying patients at risk for relapse after surgical resection is one of the important challenges today. MicroRNAs (miRNAs) regulate hundreds of genes central to maintaining a cancer phenotype. Methods: In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with ...
Ionic channel activity is involved in fundamental cellular behaviour and participates in cancerous features such as proliferation, migration and invasion which in turn contribute to the metastatic process. In this study, we investigated the expression and role of voltage-gated sodium channels in non-small-cell lung cancer cell lines. Functional voltage-gated sodium channels expression was investigated in normal and non-small-cell lung cancer cell lines. The measurement, in patch-clamp conditions, of tetrodotoxin-inhibitable sodium currents indicated that the strongly metastatic cancerous cell lines H23, H460 and Calu-1 possess functional sodium channels while normal and weakly metastatic cell lines do not. While all the cell lines expressed mRNA for numerous sodium channel isoforms, only H23, H460 and Calu-1 cells had a 250 kDa protein corresponding to the functional channel. The other cell lines also had another protein of 230 kDa which is not addressed to the membrane and might act as a dominant
PURPOSE OF REVIEW: The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, are effective as first-line treatment of advanced nonsmall cell lung cancer (NSCLC) harboring activating EGFR mutations (deletions in exon 19 and exon 21 L858R mutation). EGFR T790 M resistance mutation (EGFR T790 M) ultimately emerged in most of these patients. The second and third-generation EGFR-TKIs were designed to have more potent inhibition of EGFR and to overcome EGFR T790 M. This review describes the recent developments of these novel EGFR-TKIs.. RECENT FINDINGS: The second-generation EGFR-TKIs, afatinib and dacomitinib, irreversibly bind to the tyrosine kinase of EGFR and other ErbB-family members. Afatinib has been approved as first-line treatment of advanced NSCLC harboring activating EGFR mutations. Dacomitinib is under development. Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, ...
Nieder, Carsten; Andratschke, Nicolaus H; Guckenberger, Matthias (2015). A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question? Annals of Translational Medicine, 3(11):148-151. ...
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the g
Objective: To explore the effect of Ape1/Ref-1 on injury caused by stereotactic ablative radiotherapy in the treatment of early stage non-small cell l..
BioAssay record AID 81529 submitted by ChEMBL: Cytotoxicity against NCI tumor panel, HOP-92 non small-cell lung cancer cell line.
This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previo
SOTIO presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa.
Abstract: ABSTRACT Although many mouse models of lung adenocarcinoma exist, there is no mouse lung squamous cell carcinoma model that has been validated for use in preclinical lung cancer chemoprevention studies. Since most clinical chemoprevention trials of lung cancer are performed in subjects with bronchial dysplasia, development of a lung squamous cell carcinoma mouse model becomes one of the highest priorities. We have shown that lung squamous cell carcinomas can be induced chemically in several strains of mice (Wang et al. 2004) and that green tea polyphenols exhibit a significant efficacy against the development of lung squamous cell carcinomas (preliminary data section). In this proposal, we will use a standardized green tea preparation called Polyphenon E (PE) and its major component, EGCG. The overall objective of this proposal is to determine the efficacy of green tea polyphenols in a mouse lung squamous cell carcinoma model and to determine the molecular mechanism that underlies the ...
TY - JOUR. T1 - Inhibitory effect of dihydroaustrasulfone alcohol on the migration of human non-small cell lung carcinoma A549 cells and the antitumor effect on a Lewis lung carcinoma-bearing tumor model in C57BL/6J mice. AU - Chen, Shuo Chueh. AU - Chien, Yi Chung. AU - Pan, Chun Hsu. AU - Sheu, Jyh Horng. AU - Chen, Chih Yi. AU - Wu, Chieh Hsi. PY - 2014/1. Y1 - 2014/1. N2 - There are many major causes of cancer death, including metastasis of cancer. Dihydroaustrasulfone alcohol, which is isolated from marine coral, has shown antioxidant activity, but has not been reported to have an anti-cancer effect. We first discovered that dihydroaustrasulfone alcohol provided a concentration-dependent inhibitory effect on the migration and motility of human non-small cell lung carcinoma (NSCLC) A549 cells by trans-well and wound healing assays. The results of a zymography assay and Western blot showed that dihydroaustrasulfone alcohol suppressed the activities and protein expression of matrix ...
TY - JOUR. T1 - Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells. AU - Niiya, Masami. AU - Niiya, Kenji. AU - Shibakura, Misako. AU - Asaumi, Noboru. AU - Yoshida, Chikamasa. AU - Tanimoto, Mitsune. PY - 2006/3. Y1 - 2006/3. N2 - We previously demonstrated the doxorubicin-induced expression of urokinase-type plasminogen activator (uPA), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α in human RCK8 lymphoma cells and NCI-H69 small cell lung carcinoma cells in which reactive oxygen species might be involved. Amurubicin hydrochloride (AMR), a novel derivative drug of doxorubicin, was recently introduced to clinical practice for treatment of lung cancer in Japan. Therefore, we investigated the effects of AMR on the expression of uPA and chemokines in NCI-H69 cells. AMR and its active form, amurubicinol hydrochloride (AMROH), both induced the expression of uPA, IL-8 and MCP-1 in H69 cells in a dose-dependent ...
TY - JOUR. T1 - Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations. T2 - The okayama lung cancer study group trial 1001. AU - Ichihara, Eiki. AU - Hotta, Katsuyuki. AU - Nogami, Naoyuki. AU - Kuyama, Shoichi. AU - Kishino, Daizo. AU - Fujii, Masanori. AU - Kozuki, Toshiyuki. AU - Tabata, Masahiro. AU - Harada, Daijiro. AU - Chikamori, Kenichi. AU - Aoe, Keisuke. AU - Ueoka, Hiroshi. AU - Hosokawa, Shinobu. AU - Bessho, Akihiro. AU - Hisamoto-Sato, Akiko. AU - Kubo, Toshio. AU - Oze, Isao. AU - Takigawa, Nagio. AU - Tanimoto, Mitsune. AU - Kiura, Katsuyuki. PY - 2015/3/30. Y1 - 2015/3/30. N2 - Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as ...
Excerpt:. Patients with advanced non-small-cell lung cancer survive four months longer with fewer side effects on an immunotherapy drug called atezolizumab compared to chemotherapy, according to a phase 3 clinical trial published in The Lancet.. The trial enrolled 1225 advanced non-small-cell lung cancer patients who have no more treatment options, but this study used an early analysis of the first 850 patients from the trial. Half of the group were given atezolizumab and the other half were given docetaxel chemotherapy, which is the standard treatment for advanced non-small-cell lung cancer.. Patients given atezolizumab - a drug that blocks the programmed death ligand 1 (PD-L1) protein - survived for an average of 13.8 months, compared with 9.6 months for those on chemotherapy.. Go to full article.. ...
This study compares administration schedules of experimental MPDL3280A (antibody- a protein produced by the bodys immune system) and stereotactic ablative radiotherapy in treating patients with lung cancer. MPDL3280A, may block tumor growth in different ways by targeting certain cells. Stereotactic ablative radiotherapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Giving MPDL3280A with stereotactic ablative radiotherapy may be a better treatment for lung cancer. However, it is not yet known what the best administration schedule is for these treatments. ...
Tumour angiogenesis is an important factor for tumour growth and metastasis. Although some recent reports suggest that microvessel counts in non-small cell lung cancer are related to a poor disease outcome, the results were not conclusive and were not compared with other molecular prognostic markers. In the present study, the vascular grade was assessed in 107 (T1,2-N0,1) operable non-small cell lung carcinomas, using the JC70 monoclonal antibody to CD31. Three vascular grades were defined with appraisal by eye and by Chalkley counting: high (Chalkley score 7-12), medium (5-6), and low (2-4). There was a significant correlation between eye appraisal and Chalkley counting (P | 0.0001). Vascular grade was not related to histology, grade, proliferation index (Ki67), or EGFR or p53 expression. Tumours from younger patients had a higher grade of angiogenesis (P = 0.05). Apart from the vascular grade, none of the other factors examined was statistically related to lymph node metastasis (P | 0.0001). A
A specific, acquired chromosomal abnormality (deletion 3p) has been found in at least one chromosome 3 in 100 percent of the metaphases in 12 of 12 cell lines cultured from human small-cell lung cancer tissue and in 2-day tumor culture specimens from three patients. Analysis of the shortest region of overlap shows the deletion to be 3p(14-23). This specific change was not seen in five of five lung cancer cell lines other than small-cell lung cancer or in two lymphoblastoid lines cultured from cells of small-cell lung cancer patients whose tumors had the 3p deletion. ...
Metastasis to the lung Lung nodule Horn L, Lovly CM (2018). "Chapter 74: Neoplasms of the lung". In Jameson JL, Fauci AS, ... Sarcomas of the lung. Some rare vascular tumors of the lung Non-lung tumors which may grow into the lungs: Mediastinal tumors ... Lung tumors are neoplastic lung nodules. These include: Primary tumors of the lung/pulmonary system: Bronchial leiomyoma, a ... of the lung Pulmonary carcinoid tumor Pleuropulmonary blastoma Neuroendocrine tumors of the lung Lymphomas of the lung. ...
Usman M, Moore W, Talati R, Watkins K, Bilfinger TV (June 2012). "Irreversible electroporation of lung neoplasm: a case series ... The trial included patients with primary and secondary lung malignancies and preserved lung function. The expected ... In a prospective, single-arm, multi-center, phase II clinical trial, the safety and efficacy of IRE on lung cancers were ... A major obstacle of IRE in the lung is the difficulty in positioning the electrodes; placing the probes in parallel alignment ...
Approximately 99% of lung cancers are carcinoma, a term that indicates that the malignant neoplasm is composed of, or descended ... Combined small cell lung carcinoma (or c-SCLC) is a form of multiphasic lung cancer that is diagnosed by a pathologist when a ... April 2008). "Genetic alterations in combined neuroendocrine neoplasms of the lung". Mod. Pathol. 21 (4): 414-22. doi:10.1038/ ... "Small Cell Lung Cancer Treatment". 1980-01-01. Wittekind C, Greene FL, Henson DE, Hutter RV, Sobin LH (2003). "Lung". In ...
"Lung folding simulating peripheral pulmonary neoplasm (Blesovsky's syndrome)". Thorax. 35 (12): 936-940. doi:10.1136/thx.35.12. ... folded lung or Blesovsky syndrome), an outer portion of the lung slowly collapses as a result of scarring and shrinkage of the ... findings can include lung opacification and/or loss of lung volume. Post-surgical atelectasis will be bibasal in pattern. Chest ... It is often called a collapsed lung, although that term may also refer to pneumothorax. It is a very common finding in chest X- ...
Spivach A, Borea B, Bertoli G, Daris G (July 1976). "[Primary lung neoplasm of rare incidence: giant cell carcinoma]". Minerva ... The new paradigm recognizes that lung cancers are a large and extremely heterogeneous family of malignant neoplasms, with over ... Travis WD (November 2010). "Sarcomatoid neoplasms of the lung and pleura". Arch. Pathol. Lab. Med. 134 (11): 1645-58. doi: ... About 1% of lung cancers are sarcomas, germ cell tumors, and hematopoietic tumors, while 99% of lung cancers are carcinoma. ...
Chatzopoulos K, Boland JM (January 2021). "Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4- ... of the neoplasms associated with the BRD4-NUTM1 fusion gene. These questions also apply to a wide range of neoplasms that have ... Lung sarcomas: Four cases, one each with a BRD4-NUTM1, MDX4-NUTM1, CIC-NUTM1, or MGA-NUTM1 fusion gene. Kidney sarcomas: Three ... It is generally accepted that the BRD4-NUT protein promotes these neoplasms by maintaining their neoplastic cells in a ...
Tang VK, Vijhani P, Cherian SV, Ambelil M, Estrada-Y-Martin RM (2018). "Primary pulmonary lymphoproliferative neoplasms". Lung ... In rare cases it may not even involve the lung. The lesions in EBV+ LG consist of occasional large, atypical B cells located in ... This LPD occurs primarily in middle aged males (male:female ratio 2:1). EBV+ LG usually (~90% of cases) presents as a lung ... Dalia S, Shao H, Sagatys E, Cualing H, Sokol L (October 2014). "Dendritic cell and histiocytic neoplasms: biology, diagnosis, ...
Maleki Z (March 2011). "Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid ... Lung cancer is a large and exceptionally heterogeneous family of malignancies. Over 50 different histological variants of lung ... Lung Cancer Home Page. The National Cancer Institute site containing further reading and resources about lung cancer. [1]. ... The true incidence and prevalence of basaloid squamous cell lung carcinoma remains unknown, but this form of lung cancer is ...
General etiologies include infections, interstitial lung diseases, pulmonary edema, pulmonary hemorrhage, and neoplasm. A ... GGOs can be seen in normal lungs. Upon expiration there is less air in the lungs, leading to a relative increase in density of ... Although it can sometimes be seen in normal lungs, common pathologic causes include infections, interstitial lung disease, and ... When a substance other than air fills an area of the lung it increases that area's density. On both x-ray and CT, this appears ...
A number of disorders have been mapped in the vicinity of this gene, most notably lung neoplasms. GRCh38: Ensembl release 89: ...
Ramus developed pneumonia in January of 2007, and doctors found a neoplasm in his lungs. He opted out of surgery that could ...
... is a very rare malignant neoplasm originating from bronchial glands. It is classified as a ... Lung Cancer Home Page The National Cancer Institute site containing further reading and resources about lung cancer. World ... 2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification ... v t e (Articles with short description, Short description matches Wikidata, Lung cancer, All stub articles, Respiratory disease ...
The cancers included cancer of the brain, lung, bowel, breast, and bladder, and other neoplasms. It has been hypothesised[by ...
Lung cancer is an extremely heterogeneous family of malignant neoplasms, with well over 50 different histological variants ... Epithelial-myoepithelial carcinoma of the lung is a very rare histologic form of malignant epithelial neoplasm ("carcinoma") ... correct classification of lung cancer cases are necessary to assure that lung cancer patients receive optimum management. The ... Rossi G, Marchioni A, Sartoril G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and ...
Cancer (including neoplasms in the mammalian lung, oral/nasal cavities, thyroid and adrenal glands, and liver, squamous cell ...
Other side effects may include liver disease, lung disease, lymphoma, and severe skin rashes. People on long-term treatment ... and trophoblastic neoplasms. Methotrexate is used as a disease-modifying treatment for some autoimmune diseases, including ... It is effective for the treatment of a number of cancers, including breast, head and neck, leukemia, lymphoma, lung, ... Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and ...
... lung, pancreas, and colon neoplasms. PELP1 signaling contributes to hormonal therapy resistance. Altered localization of PLP1 ... AR, PELP1 and Src form constitutive complexes in prostate neoplasms model cells that exhibit androgen independence. Cytoplasmic ... and leucine-rich protein PELP1 in non-small cell lung cancer". Biomedicine & Pharmacotherapy. 73: 97-101. doi:10.1016/j.biopha. ...
Recurrence of lung cancer Horn L, Lovly CM (2018). "Chapter 74: Neoplasms of the lung". In Jameson JL, Fauci AS, Kasper DL, ... Lung cancer, also known as lung carcinoma (since about 98-99% of all lung cancers are carcinomas), is a malignant lung tumor ... list on each side Stage IIIA lung cancer Stage IIIB lung cancer Stage IIIB lung cancer Stage IV lung cancer Treatment for lung ... Diagrams of main features of staging Stage IA and IB lung cancer Stage IIA lung cancer Stage IIB lung cancer One option for ...
Large-cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed ... Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC ... of lung cancers. Historically, adenocarcinoma was more often seen peripherally in the lungs than SCLC and squamous-cell lung ... Non-Small Cell Lung Cancer at eMedicine "What Is Non-Small Cell Lung Cancer?". www.cancer.org. Smokers defined as current or ...
... is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical ... G1 and G2 neuroendocrine neoplasms are called neuroendocrine tumors (NETs) - formerly called carcinoid tumours. G3 neoplasms ... small-cell lung cancer (SCLC) large cell neuroendocrine carcinoma of the lung (LCNEC) Extrapulmonary small cell carcinomas ( ... Although there are many kinds of NETs, they are treated as a group of tissue because the cells of these neoplasms share common ...
... is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical ... This gene is a sensitive marker for neuroendocrine differentiation of human lung tumors. INSM1 has been shown to interact with ...
... in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue. Lung cancer is an ... "What You Need to Know About Lung Cancer". Kling, Jim (5 November 2010). "Lung-Sparing Surgery Effective for Early-Stage Lung ... curing lung cancer, (2) controlling lung cancer, and (3) being comfortable. In most cases, the goal of lung cancer surgery is ... While lung cancer is the deadliest cancer, a stigma surrounds the disease that it is highly preventable by not smoking. Lung ...
In the 2000s, scientific research conducted by the institution focused on various domains: neoplasm, injury and their ... Colorectal and Oncological Surgery Department of Plastic Surgery Department of Ophthalmology Department of Lung Diseases, ... Neoplasms and Tuberculosis Department of Infectious Diseases and Hepatology Department of Dermatology and Venereology ...
... and other neoplasms (e.g., lung cancer, lymphoma, and leukemia). Diet may also modulate risk. For example, among immigrants in ... chronic lung disease, malnutrition, and alcoholism. A person's genetics also play a role. People with silicosis have an ...
... malignant neoplasm of bronchus or lung (4.6%), Acute myocardial infarction (3%), pneumonia (2.2%), exposure to unspecified ... malignant neoplasm of pancreas (1.1%), malignant neoplasm of prostate (1.1%), malignant neoplasm of bladder (0.8%). Recently, ... factor, unspecified place (2.1%), acute kidney injury (1.4%), intra-cerebral hemorrhage (1.2%), malignant neoplasm of colon ( ...
Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Lung Abscess Chapter 123: Infective Endocarditis Chapter 124: Infections of the Skin, Muscles, and Soft Tissues Chapter 125: ... Lung Transplantation Part 8: Critical Care Medicine Section 1: Respiratory Critical Care Chapter 293: Approach to the Patient ... Interstitial Lung Disease Chapter 288: Disorders of the Pleura Chapter 289: Disorders of the Mediastinum Chapter 290: Disorders ...
... and lung neoplasms. A small amount of the rat population was able to clear particulate curium sesquioxide from the lungs, ... "Dose Responses from Inhaled Monodisperse Aerosols of 244Cm203 in the Lung, Liver and Skeleton of F344 Rats and Comparison with ... suggesting that curium sesquioxide is partially soluble in lung fluid. Curium(III) oxide is heavily used in industrial grade- ...
... lung cancer, pediatric neoplasms, stereotactic radiosurgery, radiosensitization, combined modality therapies, altered ... He has run numerous multimodality clinical trials at the national level for both adult and pediatric CNS neoplasms. Current ... Combined modality treatment of tumors of the CNS and thorax, as well as pediatric neoplasms: integrating systemic chemotherapy ...
About 0.5% to 1% of all primary malignant lung tumors are childhood tumors of the lung, making it a rare form of neoplasm. ... Retinoblastoma is a rare form of eye neoplasm (found in the retina) that is mostly found in children, being the most common ... This type of malignant neoplasm mimics pancreatic development at 7 weeks of gestation and tends to affect, most commonly, young ... that resemble the lung at week 10 to 16 of gestation. The symptoms for this disease are non-specific, and radiologic features ...
... mental retardation Thymic carcinoma Thymic epithelial tumor Thymic renal anal lung dysplasia Thymoma Thymus neoplasm ... Temtamy-Shalash syndrome TEN Ter Haar-Hamel-Hendricks syndrome Ter Haar syndrome Teratocarcinosarcoma Teratoma Testes neoplasm ... syndrome Tolosa-Hunt syndrome Toluene antenatal infection Tomaculous neuropathy Tome-Brune-Fardeau syndrome Tongue neoplasm ... Trisomy 14 mosaicism Trisomy 2 mosaicism Trisomy 3 mosaicism Trisomy 6 Trisomy Trochlear dysplasia Trophoblastic Neoplasms ( ...
Myung SK, Ju W, Kim SC, Kim H (October 2011). "Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a ... In advanced disease, metastases may be present in the abdomen, lungs, or elsewhere. Symptoms of advanced cervical cancer may ... and X-ray examination of the lungs and skeleton, and cervical conization. However, the current system allows use of any imaging ...
The World Health Organization (2019) classified papillary neoplasms (i.e. benign or cancerous tumors) of the breast into 5 ... 1 to lung and 1 to bone. By the end of the study, 47 individuals had no evidence of disease and 2 had died of unknown causes. ... Brogi E, Krystel-Whittemore M (January 2021). "Papillary neoplasms of the breast including upgrade rates and management of ... Tay TK, Tan PH (June 2021). "Papillary neoplasms of the breast-reviewing the spectrum". Modern Pathology. 34 (6): 1044-1061. ...
TTC39A has been tested for association to diseases like breast neoplasms and is expected to have molecular binding function and ... TTC39B is expressed in a multitude of tissues: testis, lung, islets of langerhans, pancreas, kidney, pooled germ cell tumors, ...
... ocular Colobomata unilobar lung heart defect Colobomatous microphthalmia heart disease hearing Colobomatous microphthalmia ... Carrington syndrome Cartilage hair hypoplasia like syndrome Cartilage-hair hypoplasia Cartilaginous neoplasms Cartwright-Nelson ... diffuse Cystic fibrosis gastritis megaloblastic anemia Cystic fibrosis Cystic hamartoma of lung and kidney Cystic hygroma ... hypoxia Cerebral malformations hypertrichosis claw hands Cerebral palsy Cerebral thrombosis Cerebral ventricle neoplasms ...
For example, neoplasms characterized by high-grade features, invasive glands and or signet ring cells, are termed ... lung, breast, fallopian tubes, and the pancreas. This disease is often discovered during surgery for other conditions, e.g., ... Young RH (May 2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Seminars in ... ISBN 978-0-323-35909-2. Sugarbaker PH (January 2006). "New standard of care for appendiceal epithelial neoplasms and ...
IV Leiomyomas Video (Articles with short description, Short description is different from Wikidata, Benign neoplasms). ... in which the masses appear in more distant locations such as the lung and lymph nodes. Uterine fibroids Worley Jr, M.; Aelion, ...
Comparison of Neoplasms in Six Sources of Rats Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed. ... Hsu CC, Lai SC (December 2007). "Matrix metalloproteinase-2, -9 and -13 are involved in fibronectin degradation of rat lung ... The Lewis rat suffers from several spontaneous pathologies: first, they can suffer from high incidences of neoplasms, with the ... A 1972 study compared neoplasms in Sprague Dawley rats from six different commercial suppliers and found highly significant ...
However, p16 can be expressed in other neoplasms and in several normal human tissues. More than a third of urinary bladder SCCs ... Carriers of germline mutations in CDKN2A have, besides their high risks of melanoma, also increased risks of pancreatic, lung, ... Balgkouranidou I, Liloglou T, Lianidou ES (February 2013). "Lung cancer epigenetics: emerging biomarkers". Biomarkers in ... infection and neoplasms of cervical origin. The majority of SCCs of uterine cervix express p16. ...
In the United Kingdom, it is the second-most common cause of cancer death after lung cancer, where around 35,000 cases are ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... Prostate cancer is the third-leading cause of cancer death in men, exceeded by lung cancer and colorectal cancer. It accounts ... Further investigation with this substance revealed that it could interfere with the LT receptors in the lung carcinoma [38]. In ...
High miR-708 expression levels are observed in lung cancers due to their oncogenic role in lung cancer tumour growth and ... "miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets ... Xing L, Todd NW, Yu L, Fang H, Jiang F (August 2010). "Early detection of squamous cell lung cancer in sputum by a panel of ... "Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after ...
Individuals with extracavitary PEL present with lesions in the lung, central nervous system, gastrointestinal tract, and/or ... This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... List of hematologic conditions Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A ... lungs, central nervous system, testes, paranasal sinuses, muscle, and, rarely, inside the vasculature and sinuses of lymph ...
... the main reason for lung cancer) had high incidences of lung cancer. Modern mining practices greatly reduce the danger from ... Several severe adverse health effects, such as an increased incidence of cancers, thyroid diseases, CNS neoplasms, and possibly ... lung, colon, and thyroid tissues as the most radiosensitive among women. For example, the FGR 13 has estimated that the ratio ... who were affected by disproportionately high incidences of fatal lung cancer caused by radon exposure. In fact, the health ...
Margolese RG, Fisher B, Hortobagyi GN, Bloomer WD (2000). "Neoplasms of the Breast". In Bast RC, Kufe DW, Pollock RE, et al. ( ... for example in the study of the link between smoking and lung cancer. Statistical analysis along with the biological sciences ...
Lung cancers have been found to include four different subsets of dendritic cells: three classical dendritic cell subsets and ... Blastic plasmacytoid dendritic cell neoplasm is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... Blastic plasmacytoid dendritic cell neoplasm has a high rate of recurrence following initial treatments with various ...
Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck ... Metastasis have been reported to develop in various sites including the lungs, pleura, lymph nodes, bones, thoracic cavity, ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... "European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel". CA: A Cancer Journal for ... for lung cancer, see Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, ... Cancers such as lung cancer and mesothelioma can come from inhaling tobacco smoke or asbestos fibers, or leukemia from exposure ...
Hemorrhagic neoplasms are more complex, heterogeneous bleeds often with associated edema. These hemorrhages are related to ... Glioblastomas are the most common primary malignancies to hemorrhage while thyroid, renal cell carcinoma, melanoma, and lung ... of consciousness Hypertension Arteriovenous malformation Aneurysm rupture Cerebral amyloid angiopathy Intracranial neoplasm ...
CD10+ differentiates mucinous cystic neoplasms (CD10+/CK20+) from intraductal papillary mucinous neoplasm of branch duct type ( ... variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux". Cancer Res. 56 ... Neprilysin is also associated with other biochemical processes, and is particularly highly expressed in kidney and lung tissues ... Murali R, Delprado W (2005). "CD10 immunohistochemical staining in urothelial neoplasms". Am. J. Clin. Pathol. 124 (3): 371-9. ...
Kales SC, Ryan PE, Nau MM, Lipkowitz S (June 2010). "Cbl and human myeloid neoplasms: the Cbl oncogene comes of age". Cancer ... "Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras ... "DNA copy number losses in human neoplasms". The American Journal of Pathology. 155 (3): 683-94. doi:10.1016/S0002-9440(10)65166 ... "Deubiquitinase function of A20 maintains and repairs endothelial barrier after lung vascular injury". Cell Death Discovery. 4 ( ...
Ureteral neoplasm, a type of tumor that can be primary, or associated with a metastasis from another site Urethral cancer, ... lung, liver, bone, etc.) Other classifications of transitional cell cancer of the ureter include localized, regional, ...
Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... lung cancer, brain cancer, melanoma of the eye or skin, salivary gland tumors, and Kaposi's sarcomas. While some of these ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Choi SM, O'Malley DP (December 2018). "Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms". ...
NCI-H1688, a human lung carcinoma cell line that displays multidrug resistance, also overexpress p95 (NCA-90) and H19. No other ... In contrast to most other cancers, adrenocortical neoplasms appear to have decreased expression of H19. To determine a possible ... Downregulation of H19 in breast and lung cancer cells decreases their clonogenicity and anchorage-dependent growth Subcutaneous ... esophageal cancer and lung cancer. Cellular DNA integrity is often compromised in cancer. Genome instability can refer to the ...
... neoplasms can be separated into Hürthle cell adenomas and carcinomas, which are respectively benign and malignant ... On few occasions, patients with Hürthle cell carcinoma have distant metastases in the lungs or surrounding bones. Hürthle cell ... Some scientists have identified these mutations as deletions in the mitochondrial DNA of Hürthle cells found in neoplasms and ... References for findings: - Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D. "Hürthle cell neoplasm". Pathology Outlines.{{cite ...
It is a malignant neoplasm and is one of the most treatable and curable cancers, with a survival rate above 95% if discovered ... Stage 3 seminoma is characterized by the presence of metastasis outside the retroperitoneum-the lungs in "good risk" cases or ...
FEN1 is upregulated in the majority of cancers of the breast, prostate, stomach, neuroblastomas, pancreas, and lung.[citation ... Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms).[verification needed] Investigation ... of non-small-cell lung cancers. Epigenetic upregulation of the DNA repair genes PARP1 and FEN1 occurs in numerous cancers (see ...
... bronchus and lung cancers and chronic obstructive pulmonary disease. More than half of all consultations with GPs in Australia ... 2nd Neoplasms (accounting for 172.8 deaths per 100,000 population) and 3rd Chronic Respiratory Disease (59.25 deaths per ... 2nd Neoplasms (accounting for 201.65 deaths per 100,000 population), 3rd Neurological Disorders (accounting for 76.18 deaths ... neoplasms - 3,751 DALYs per 100,000 population mental disorders - 3,216 DALYs per 100,000 musculoskeletal disorders - 2,956 ...
Articles with short description, Short description is different from Wikidata, Epidermal nevi, neoplasms, and cysts, Conditions ... lungs, and/or bones. Malignant CCS tumors occur more often in older individuals and tend to be larger (i.e. ranging up to 17.5 ... Trichofolliculoma Spiradenoma spiradenocarcinoma List of cutaneous conditions List of cutaneous neoplasms associated with ... lung cancer, and human papillomavirus-associated cancers. In a study of 95 mutations in CCS, 48% were frameshift, 27% were ...
For example, non-melanoma skin cancer, head and neck cancer, breast cancer, non-small cell lung cancer, cervical cancer, anal ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... such as the lungs. Some doctors say an advantage to stereotactic treatments is that they deliver the right amount of radiation ... and lung. Unfortunately, IMRT is limited by its need for additional time from experienced medical personnel. This is because ...
Velayos, FS; Williamson, A; Sousa, KH; Lung, E; Bostrom, A; Weber, EJ; Ostroff, JW; Terdiman, JP (June 2004). "Early predictors ... H7 Shigella Salmonella Campylobacter jejuni Hemorrhoids Neoplasm - such as colorectal cancer Angiodysplasia Bleeding from a ...
Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... lungs, gastrointestinal tract, bone, sinuses, ears, and/or testes. The disease may also present as a pDC leukemia, i.e. ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ... pDCs that undergo malignant transformation cause a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm. In ...
Clinical and epidemiological characteristics of lung cancer cases in Qatar  Ibrahim, W.H.; Rasul, K.I.; Khinji, A.; Ahmed, M.S ... We conducted a lung cancer risk assessment for internal exposure to naturally occurring [‎222]‎Rn gas both indoor and outdoor. ... Study Group on Epidemiology of Cancer of the Lung; World Health Organization (‎Organisation mondiale de la Santé, 1960)‎ ... Study Group on Epidemiology of Cancer of the Lung; World Health Organization (‎Organización Mundial de la Salud, 1960)‎ ...
mesothelioma AND Neoplasms AND Lung , Recruiting, Not yet recruiting, Available Studies , Last update posted in the last 30 ... mesothelioma AND Neoplasms AND Lung , Recruiting, Not yet recruiting, Available Studies , Last update posted in the last 30 ... 24 Studies found for: mesothelioma AND Neoplasms AND Lung , Recruiting, Not yet recruiting, Available Studies , Last update ...
Lung cancer] / A. Kh. Trakhtenberg. by Trakhtenberg, A. K.. Material type: Text; Format: print Publication details: Moscow : ... Diagnosis of the lung cancer in polyclinics] / R. I. Wagner, A. S. Barchuk, N. N. Blinov. by Wagner, R. I , Barchuk, A. S , ... The Endocrine lung in health & disease / [edited by] Kenneth L. Becker, Adi F. Gazdar. by Becker, Kenneth L , Gazdar, Adi F. ... Lung cancer / edited by E. L. Wynder and S. Hecht. by Wynder, Ernest Ludwig , Hecht, S , International Union against Cancer. ...
Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor . ... Lung neoplasms. *Malignant lung tumor. *Malignant neoplasm of lung. *Malignant tumor of lung ... Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of ... Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 ...
Diagnostic value of needle biopsy of lung in pulmonary neoplasm. Journal of the Association of Physicians of India. 1962 Apr; ...
EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung ... National Lung Screening Trial Research Team; Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D ... followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading ... Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. ...
Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest ... Efthymiou CA, Masudi T, Thorpe JA, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung. Five-year ... Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögrens syndrome: a literature review. Ther ...
Lung Diseases, Obstructive [‎19]‎. Lung Neoplasms [‎49]‎. Lupus Coagulation Inhibitor [‎1]‎. Lupus Erythematosus, Systemic [‎3 ...
Neuroendocrine neoplasms of the lung. L A Cerilli, J H Ritter, S E Mills, M R Wick ... Neuroendocrine tumors of the lung continue to be difficult nosologic and diagnostic problems, centering on the time-honored ... This review considers the epithelial and nonepithelial lesions of the lung that may demonstrate neuroendocrine and ... Problems that are encountered in the classification of such neoplasms revolve around the differing criteria that have been ...
Bronchus or lung, unspecified - Malignant neoplasms (152). *Chronic obstructive pulmonary disease, unspecified (97) ...
Neoplasms of the lung. In: Harrisons Principles of Internal Medicine, 16th edition. TR Harrison et al., editors. New York NY: ... Bach P, Mirkin J, Oliver T, Azzoli C, Berry D, Brawley O. Benefits and harms of CT screening for lung cancer: a systematic ... Lung cancer screening in the occupational setting- an update. Washington DC [updated 2012 August 2; accessed on 2012 October 18 ... Work-related lung disease surveillance report 2007. Department of Health and Human Services, Centers for Disease Control and ...
Lung-cancer; Lung-disorders; Neoplasms; Surveillance ... Occupational and environmental lung diseases: diseases from ... Occupational and environmental lung diseases: diseases from work, home, outdoor, and other exposures ...
Lung neuroendocrine neoplasms (lung NENs) are categorised by morphology, defining a classification sometimes unable to reflect ... Lung neuroendocrine neoplasms (lung NENs) are categorised by morphology, defining a classification sometimes unable to reflect ... Automated analysis of proliferating cells spatial organisation predicts prognosis in lung neuroendocrine neoplasms. Bulloni M.; ... the well-recognised prognostic role of Ki-67 Labelling Index on a multi-centre dataset comprising the most controversial lung ...
The most common indication for bronchospasm is lung neoplasm. [1] Various novel techniques have been used to treat a wide range ... In typical lung resection procedures, any airway involved with tumor is resected with its associated lung parenchyma. This ... Perioperative Lung Function Monitoring for Anatomic Lung Resections. Ann Thorac Surg. 2017 Nov. 104 (5):1725-1732. [QxMD ... Unlocking the Secrets of Immunotherapy for Metastatic Non-Small Cell Lung Cancer: What Do Nurses Need to Know? 0.5 CE Credits ...
... other unclassified lung diseases); malignant neoplasm of trachea, bronchus, and lung; disorders involving the immune mechanism ...
... en. ... Liver embolisation for patients with neuroendocrine neoplasms: systematic review induced lymphocytopenia in lung cancer. ... Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms ... Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. ...
Lung-cancer; Lung-disorders; Neoplasms; Surveillance ... Occupational and environmental lung diseases: diseases from ... Occupational and environmental lung diseases: diseases from work, home, outdoor, and other exposures ...
Categories: Lung Neoplasms Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted 2 ...
Primary Phenotype: Lung Neoplasms * Adenocarcinoma * Neoplasms, Squamous Cell Links to Related Genes * BRCA2 ... the UK lung cancer GWAS from the Institute for Cancer Research (ICR-GWAS)2; the NCI lung cancer GWAS (NCI-GWAS)3, the IARC lung ... The hospital based case-control lung cancer study from Estonia8,9; and (v) The population-based HUNT2/Troms IV lung cancer ... Transdisciplinary Research Into Cancer of the Lung (TRICL) - Meta Analysis. A sub-study of Transdisciplinary Research Into ...
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies ...
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies ...
ICD-10 code C34.30 for Malignant neoplasm of lower lobe, unspecified bronchus or lung online definition ... ICD-10 code C34.30 for Malignant neoplasm of lower lobe, unspecified bronchus or lung ... Malignant neoplasms, stated or presumed to be primary (of specified sites), and certain specified histologies, except ...
Our study suggests that ISL inhibits lung cancer cell migration and tumorigenesis by interfering with Src through its ... Lung Neoplasms / drug therapy* * Lung Neoplasms / metabolism * Lung Neoplasms / pathology * Mice * Mice, Nude ... Suppression of lung cancer progression by isoliquiritigenin through its metabolite 2, 4, 2, 4-Tetrahydroxychalcone J Exp Clin ... Results: Using a panel of lung cancer cell lines, ISL was identified as the only licorices constituent capable of inhibiting ...
Lung Neoplasms. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung Diseases. Respiratory Tract ... Purpose: Patients with peripheral lung nodules require evaluation for lung cancer. Our aim is to assess the diagnostic yield of ... Target population: Patients referred for bronchoscopy and lung biopsies as a part of their work up for peripheral lung lesions ... The increase in sensitivity for diagnosing lung cancer with the addition of cryobiopsy to standard forceps biopsy for a ...
The top cause of death in the general population is neoplasm of the lungs. Aspiration of the lung is near the top for those who ... died from epilepsy, but the mechanisms leading to lung-related deaths in these populations may differ, said Mbizvo. ...
Lung Neoplasms, Not Specified as Malignant ... View other providers who treat Lung Neoplasms, Not Specified as ...
Mutation spectra of Kras and Tp53 in urethral and lung neoplasms in B6C3F1 mice treated with 3,3′,4,4′-tetrachloroazobenzene. ... A recent National Toxicology Program study showed B6C3F1 mice exposed to TCAB developed a treatment-related increase in lung ...
Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms. Last Updated: June 27, 2013. Status: Completed ... Other Interests & Specialties: Asthma, asbestosis lung disease, aviation medicine, breathlessness, bronchiectasis, chronic ... Winter also served as the Vice President of the British Lung Foundation. ... the United Kingdoms largest specialty cardiothoracic hospital and the countrys main heart and lung transplant center. Dr. ...
  • Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. (medlineplus.gov)
  • Large cell carcinoma arises from epithelial cells that line the lungs. (medlineplus.gov)
  • Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. (medlineplus.gov)
  • Neuroendocrine tumors of the lung continue to be difficult nosologic and diagnostic problems, centering on the time-honored terms of 'carcinoid,' 'atypical carcinoid,' and 'small cell carcinoma. (qxmd.com)
  • Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? (uc.edu)
  • [ 2 ] The spectrum of ACTH-secreting neoplasms now extends to carcinoid tumors , pheochromocytomas , medullary thyroid carcinoma , and islet cell tumors . (medscape.com)
  • Carcinoma of the ampulla of Vater tends to manifest early due to biliary outflow obstruction, as opposed to pancreatic neoplasms that often are advanced at the time of diagnosis. (medscape.com)
  • In advanced cases, lung metastasis also may occur. (medscape.com)
  • DESCRIPTION (provided by applicant): The National Lung Screening Trial (NLST) of 53,454 current and former healthy smokers demonstrated that low dose computed tomography (LDCT) was effective in detecting lung tumors at an earlier stage and increasing survival from lung cancer. (elsevier.com)
  • NETs are a group of tumors with heterogenous malignancy that evolve from neuroendocrine cells, with the lung being the second target organ after the gastrointestinal tract. (spandidos-publications.com)
  • The main purpose of this review, was the analysis of the available literature in all aspects while mainly focusing on molecular diagnosis data and secondly, by using this molecular landscape to establish a differentiation of lung neuroendocrine tumors (LNETs). (spandidos-publications.com)
  • Lung neuroendocrine tumors (LNETs) are a group of rare tumors with heterogenous malignancy originating in amine precursor uptake and decarboxylation (APUD) neuroendocrine cells from Kulchitsky cells (argentaffin cells) ( 1 ). (spandidos-publications.com)
  • In addition to the single pulmonary localizations there have been cases described of two or more carcinoid tumors or tumorlets of the lung, gastrointestinal tract and pancreas. (spandidos-publications.com)
  • Tumors or cancer of the LUNG. (bvsalud.org)
  • The role of electron microscopy in characterization of uncommon epithelial pulmonary neoplasms, metastatic neoplasms to and from lung and other tumors, including mesenchymal neoplasms. (uab.edu)
  • Because cutaneous melanomas often carry activating mutations in the BRAF gene (V600E), we performed a BRAF mutational analysis using direct sequencing for both of these tumors arising from the lung. (elsevier.com)
  • Smoking and health : summary of a report of the Royal College of Physicians of London on smoking in relation to cancer of the lung and other diseases. (who.int)
  • The lymphocytic infiltrative lung diseases. (uab.edu)
  • Acute kidney injury (AKI) is a life-threatening disease with high mortality characterized by an abrupt decrease of the kidney glomerular filtration rate, extra-kidney consequences (cardiovascular diseases, lung injury, neurological impairment) and high risk of secondary chronic kidney disease (CKD). (hrb.ie)
  • Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. (centerwatch.com)
  • Epithelioid angiosarcoma is a rare malignant neoplasm found in vascular endothelial cells. (bvsalud.org)
  • Metastatic spread involves the regional lymph nodes, lungs, and bone. (medscape.com)
  • Even if at initial stages a tumour does not seem aggressive, its central location in proximity with several other organs makes it very dangerous: the most common metastases are in the lymph nodes and in the lungs (55%), liver and bones (33%), followed by the other kidney, the brain, the spleen, the colon and the skin. (lugnani.com)
  • Somatic mutations in the TP53 , EGFR , and KRAS genes are common in lung cancers. (medlineplus.gov)
  • Tobacco smoking is the most important risk factor for lung cancer [ 1 ], while tobacco and alcohol conjointly account for the occurrence of 67-84% of the head and neck (H&N) cancers [ 2 ]. (biomedcentral.com)
  • The increased risk associated with a 5-unit increase in BMI for those with BMI of 18·5 kg/m 2 or higher was 1·09 (95% CI 1·04-1·14) for all cancers (excluding lung and upper aerodigestive tract). (elsevier.com)
  • The TTFC is an equal if not better predictor of nicotine and carcinogen uptake in smokers than cigarettes per day, which explains its association with lung cancer risk, as well as with the risk of other tobacco-related cancers. (elsevier.com)
  • The lung is the second organ, after the liver, in the localization of NETs, making up 25% of all NETs and 1-2% of all cancers ( 9 ). (spandidos-publications.com)
  • DESIGN, SETTING, AND PARTICIPANTS: Four serial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to December 31, 2010, were distributed to 3 sites that performed the following immunohistochemical assays: 28-8 antibody on the Dako Link 48 platform, 22c3 antibody on the Dako Link 48 platform, SP142 antibody on the Ventana Benchmark platform, and E1L3N antibody on the Leica Bond platform. (tamu.edu)
  • Lung neuroendocrine neoplasms (lung NENs) are categorised by morphology, defining a classification sometimes unable to reflect ultimate clinical outcome. (hunimed.eu)
  • Liver embolisation for patients with neuroendocrine neoplasms: systematic review. (openrepository.com)
  • Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. (openrepository.com)
  • Herrera GA, Alexander CB, Jones M. Ultrastructural characterization of pulmonary neoplasms I. The role of electron microscopy in characterization of the most common epithelial neoplasms. (uab.edu)
  • Herrera GA, Alexander CB, Jones M. Ultrastructural characterization of pulmonary neoplasms II. (uab.edu)
  • Nine JAK inhibitors have now been approved by agencies around the world to treat rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, ulcerative colitis, atopic dermatitis, graft versus host disease, and myeloproliferative neoplasms. (nih.gov)
  • Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor . (medlineplus.gov)
  • In typical lung resection procedures, any airway involved with tumor is resected with its associated lung parenchyma. (medscape.com)
  • Furthermore, we showed both ISL and THC suppressed in vitro lung cancer cell invasion and in vivo tumor progression. (nih.gov)
  • OBJECTIVES: I. Determine the anti-tumor effect of ZD0473 in patients with progressive or relapsed non-small cell lung cancer who have failed first-line platinum-based chemotherapy. (knowcancer.com)
  • The International Staging Committee of the International Association for the Study of Lung Cancer and the International Mesothelioma Interest Group recommend that P/D should aim to remove all macroscopic tumor involving the parietal and visceral pleura and should be termed "extended" P/D when the diaphragm or pericardium is resected. (edu.au)
  • NSCLC, non\little cell lung tumor. (ecologicalsgardens.com)
  • A recent National Tox icology Program study showed B6C3F1 mice exposed to TCAB developed a treatment-related increase in lung carcinomas in the high-dose group, and urethral carcinomas, an extremely rare lesion in rodents, in all dose groups. (21centurytoxicology.com)
  • Wnt7a-null mice under de novo conditions and in both the strains display E-cadherin-to-N-cadherin switch, reduced expression of cellular senescence markers and reduced expression of senescence-associated secretory phenotype, indicating a genetic predisposition of these mice to increased carcinogen-induced lung tumorigenesis. (arizona.edu)
  • Biologic Evaluation of Diabetes and Local Recurrence in Non-Small Cell Lung Cancer. (uc.edu)
  • Identification of stage I non-small cell lung cancer patients at high risk for local recurrence following sublobar resection. (uc.edu)
  • Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 2. (uc.edu)
  • Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. (tamu.edu)
  • Pneumonic-type mucinous lung adenocarcinoma diagnosed by transbronchial cryobiopsy. (uc.edu)
  • Diagnosis of the lung cancer in polyclinics] / R. I. Wagner, A. S. Barchuk, N. N. Blinov. (who.int)
  • Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review. (medscape.com)
  • Active smoking at the time of diagnosis of a first head & neck (H&N) or lung cancer is associated with a worse cancer outcome and increased mortality. (biomedcentral.com)
  • At the time of diagnosis of the first lung or H&N cancer, current smoking is highly associated with previous type of smoking and alcohol drinking patterns. (biomedcentral.com)
  • Consequently, little is known about whether the smoking status at the time of diagnosis of a first-time lung or H&N cancer is related to specific social or psychiatric features, lifelong smoking patterns, or history of other substance uses. (biomedcentral.com)
  • In a multicenter one-year cohort study among 371 subjects with a first-time lung or H&N cancer (i.e., the ALTAK study), we conducted a cross-sectional study using the baseline assessment to investigate the differences in social factors, psychiatric condition, and other substance use patterns between current and past-smokers at the time of the cancer diagnosis. (biomedcentral.com)
  • Successful diagnosis of lymphangioleiomyomatosis with transbronchial lung cryobiopsy. (uc.edu)
  • Clinical diagnosis was correct in 43.4% of cases suspected of tuberculosis and 69.2% of cases suspected of lung cancer. (who.int)
  • The differential diagnosis was focused on heart failure, lung disease, and occult neoplasm. (springeropen.com)
  • Aims The aim of this study was to investigate the association between oncogenic alterations and programmed cell death ligand 1 (PD-L1) expression in lung adenocarcinomas, as well as the prognostic value of KRAS and/or TP53 mutations in patients treated with immunotherapy. (bmj.com)
  • 50 years of age with slow sociation with underlying neoplasm or less or non-resolving pneumonia [ 5 ]. (who.int)
  • Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. (medlineplus.gov)
  • Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent. (medlineplus.gov)
  • Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. (doabooks.org)
  • Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. (doabooks.org)
  • In this review, we will provide a comprehensive overview of the biological rational, efficacy and safety of ADCs as therapeutic agents against non-small cell lung cancer and small cell lung cancer. (elsevier.com)
  • Association between nonpituitary or adrenal neoplasm and Cushing syndrome dates back to 1928 when Brown first described a case with small cell lung cancer with features resembling Cushing syndrome. (medscape.com)
  • We evaluated whether pivotal phase III trials of immune checkpoint blockades (ICBs) represent the overall population of non\small cell lung cancer (NSCLC) patients. (ecologicalsgardens.com)
  • This may be altered during treatment planning, and the authors have previously shown that this improves local control (LC) for non.small cell lung cancer BMs without increasing toxicity. (elsevier.com)
  • Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. (openscience.si)
  • Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). (bioseek.eu)
  • Patients with breast cancer, colorectal cancer, or lung cancer were recruited to complete the EQ-5D-3L and EQ-5D-5L questionnaires. (bsl.nl)
  • A total of 1802 cancer patients (breast cancer: 601, colorectal cancer: 601, lung cancer: 600) were included, with the mean age of 55.6 years. (bsl.nl)
  • Problems that are encountered in the classification of such neoplasms revolve around the differing criteria that have been advanced for their definition and variable application of such criteria in common practice. (qxmd.com)
  • Epithelioid angiosarcoma (EA) is a rare variant of angiosarcoma, which is characterized by a high-grade malignant neoplasm, which consists of an atypical, multilayered, or solid endothelial proliferation and vasoformative architecture, presenting necrosis and an area of hemorrhage 1-5 . (bvsalud.org)
  • Somatic mutations in many different genes have been found in lung cancer cells. (medlineplus.gov)
  • Methods This study is a retrospective cohort study of 519 patients with lung adenocarcinomas analysed for mutations and PD-L1 expression. (bmj.com)
  • AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms. (umag.cl)
  • In the United States, lung cancer is the second most commonly diagnosed cancer, after breast cancer , accounting for about one-quarter of all cancer diagnoses. (medlineplus.gov)
  • Bach P, Mirkin J, Oliver T, Azzoli C, Berry D, Brawley O. Benefits and harms of CT screening for lung cancer: a systematic review. (cdc.gov)
  • It was interesting to see that most patients lived past 90 days post-discharge, but of those who died, the number one cause of death was malignant neoplasm of an unspecified part of the bronchus or lung. (cdc.gov)
  • The study was conducted under the auspices of the Transdisciplinary Research In Cancer of the Lung (TRICL) Research Team, which is a part of the Genetic Associations and MEchanisms in ONcology (GAME-ON) consortium, and associated with the International Lung Cancer Consortium (ILCCO). (nih.gov)
  • Lung cancer is the leading cause of U.S. cancer deaths and radon is the second leading risk factor for lung cancer. (cdc.gov)
  • and radon is the second leading risk factor for lung cancer. (cdc.gov)
  • Lung cancer is the leading cause of cancer deaths, accounting for an estimated 27 percent of all cancer deaths in the United States. (medlineplus.gov)
  • Aspiration of the lung is near the top for those who died from epilepsy, but the mechanisms leading to lung-related deaths in these populations may differ, said Mbizvo. (medscape.com)
  • In areas with high potential for radon exposure, increasing knowledge about potential for radon exposure may result in increased radon testing, mitigation, or other radon reducing strategies, and ultimately reduction of lung cancer deaths. (cdc.gov)
  • 148,869 lung cancer-associated deaths occurred in 2016 (1). (bvsalud.org)
  • In 2004, lung cancer was the leading cause of death from cancer both for men (31.3% of all cancer deaths among men) and women (25.6% of all cancer deaths among women). (cdc.gov)
  • Notably, where single-gene analysis finds little similarity between two independent studies of patient survival in lung cancer, GSEA reveals many biological pathways in common. (bioseek.eu)
  • The current study proposes to study the effects of a nicotine dependence behavior, the time to first cigarette (TFFC) after waking, on the early detection of lung cancer and overall survival time in the NLST. (elsevier.com)
  • The neoplasm is highly chemosensitive and radiosensitive, and 5-year survival rates greater than 75% are not uncommon. (medscape.com)
  • Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN). (openrepository.com)
  • Purpose: Patients with peripheral lung nodules require evaluation for lung cancer. (clinicaltrials.gov)
  • Our aim is to assess the diagnostic yield of a new technique, transbronchial cryobiopsies, in patients at risk for lung cancer. (clinicaltrials.gov)
  • Target population: Patients referred for bronchoscopy and lung biopsies as a part of their work up for peripheral lung lesions. (clinicaltrials.gov)
  • Procedures: Patients enrolled will have forceps transbronchial biopsies followed by transbronchial cryobiopsies for their lung lesion during bronchoscopy. (clinicaltrials.gov)
  • In patients with a first lung or H&N cancer, the role of these risk factors was never investigated. (biomedcentral.com)
  • Enhancing the knowledge of the psychosocial determinants of the CS status among subjects with a first lung or H&N cancer could strengthen the impact of smoking cessation programs proposed to these patients. (biomedcentral.com)
  • Which factors influence the quality of life of Tunisian patients with lung cancer? (bvsalud.org)
  • Les patients en stade avancé avaient une mauvaise QDV en termes d'activités physique et émotionnelle, d' insomnie et de constipation . (bvsalud.org)
  • Les patients ayant des métastases avaient une mauvaise QDV en termes de score global, d'activité physique , de fatigue , d' insomnie , d' anorexie et de diarrhée . (bvsalud.org)
  • Introduction - No previous study has established the factors that influence the quality of life (QOL) of tunisian patients with lung cancer (LC).This study aims to identify the factors that influence QOL of tunisian patients with LC. (bvsalud.org)
  • High versus low positive end-expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome. (umag.cl)
  • We conducted a lung cancer risk assessment for internal exposure to naturally occurring [‎222]‎Rn gas both indoor and outdoor. (who.int)
  • Accumulating, yet limited, evidence points to a potential association between Hp infection and lung cancer risk. (elsevier.com)
  • Epidemiologic studies have shown that odds ratios (estimated relative risks) of lung cancer with Hp infection range from 1.24 to 17.78 compared with the controls, suggesting an increased lung cancer risk in the population exposed to Hp infection although far from supporting a causal relationship between Hp and lung cancer. (elsevier.com)
  • To improve the benefit/cost ratio, the USPSTF and the National Cancer Institute acknowledge that there is a need to identify additional lung cancer risk factors to better characterize the high risk target populations that would benefit from LDCT screening. (elsevier.com)
  • Further, radon exposure increases lung cancer risk in smokers above smoking alone. (cdc.gov)
  • Cite this: Endo Case Challenge: A 36-Year-Old Has Cramping, Lung Issues and Can't Lose Weight - Medscape - Mar 31, 2022. (medscape.com)
  • This study documents for the first time the clinical and epidemiological characteristics of lung cancer cases in Qatar from 1998 to 2005. (who.int)
  • as a treatment for B-cell neoplasms have shown some promising results in clinical trials, their clinical use is limited, partially due to the risk of cytokine-release syndrome (CRS) occurring in response to the treatment. (ajmc.com)
  • We detected a p53 mutation, which was thought to be a potential somatic mutation, in one of the two cases using a sequencing panel targeting 20 lung cancer-related genes. (elsevier.com)